Transaction DateRecipientSharesTypePriceValue
24th July 2020Plc Glaxosmithkline1,260,504Open or private purchase$2.25$2,836,134.00
21st July 2020Plc Glaxosmithkline361,111Open or private purchase$18.00$6,499,998.00
21st July 2020Plc Glaxosmithkline1,538,724Conversion of derivative$0.00
21st July 2020Plc Glaxosmithkline348,469Conversion of derivative$0.00
15th July 2020Plc Glaxosmithkline78Open or private sale$19.25$1,501.50
15th July 2020Plc Glaxosmithkline3,069Open or private sale$19.40$59,543.51
14th July 2020Plc Glaxosmithkline79,090Conversion of derivative$0.00
14th July 2020Plc Glaxosmithkline1,597Open or private sale$19.27$30,780.58
14th July 2020Plc Glaxosmithkline525,499Conversion of derivative$0.00
14th July 2020Plc Glaxosmithkline1,712,810Conversion of derivative$0.00
Bicycle Therapeutics Plc
Bicycle Therapeutics Plc logo

Based on disclosure changes, sentiment, insider trading and news impact we give a rating of 10/10.

Bicycle Therapeutics Plc engages in the development of biopharmaceuticals. It focuses on developing a novel class of medicines, which the company refers to as bicycles, for diseases that are underserved by existing therapeutics. The firm utilizes its novel and proprietary phage display platform to identify bicycles.

Ticker: BCYC
Sector: Health Technology
Industry: Biotechnology
SEC Central Index Key (CIK): 1761612
Employees: 72
Exchange: NASDAQ
Auditor Opinion:

Disclosure Language changes
Red Flags